Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications-Reference-Cited by-同舟云学术

Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications

Published:2019-08 Issue:8-9 Volume:112 Page:455-458
ISSN:1875-2136
Container-title:Archives of Cardiovascular Diseases
language:en
Short-container-title:Archives of Cardiovascular Diseases

Author:

Cokkinos Dennis V.,Cokkinos Philip,Kolovou Genovefa

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference35 articles.

1. The best in coronary artery disease management is yet to come;Angoulvant;Arch Cardiovasc Dis,2018

2. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Cholesterol Treatment Trialists’ (CTT) Collaboration;Lancet,2010

3. Ezetimibe added to statin therapy after acute coronary syndromes;Cannon;N Engl J Med,2015

4. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: determinants and prognostic impact;Bauters;Arch Cardiovasc Dis,2018

5. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;J Am Coll Cardiol,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of pro- and anti-inflammatory cytokines during anti-proprotein convertase subtilisin/kexin type 9 therapy in patients with statin-resistant familial hypercholesterolemia;Frontiers in Cardiovascular Medicine;2024-07-18

2. The Relationship Between Endocan and Serum Inflammatory Markers in Patients with Senile Calcific Aortic Stenosis;The Anatolian Journal of Cardiology;2024

3. Tissue and Serum Biomarkers in Degenerative Aortic Stenosis-Insights into Pathogenesis, Prevention and Therapy;Biology;2023-02-22

4. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study;Nutrition, Metabolism and Cardiovascular Diseases;2021-11

5. Erratum to “Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications” [Arch Cardio Dis. (2019) 455–4588];Archives of Cardiovascular Diseases;2019-10